ENTA
Price
$7.06
Change
+$0.07 (+1.00%)
Updated
Aug 8, 10:30 AM (EDT)
Capitalization
149.42M
3 days until earnings call
SCPH
Price
$4.59
Change
-$0.42 (-8.38%)
Updated
Aug 8, 10:53 AM (EDT)
Capitalization
264.49M
89 days until earnings call
Interact to see
Advertisement

ENTA vs SCPH

Header iconENTA vs SCPH Comparison
Open Charts ENTA vs SCPHBanner chart's image
Enanta Pharmaceuticals
Price$7.06
Change+$0.07 (+1.00%)
Volume$5.81K
Capitalization149.42M
scPharmaceuticals
Price$4.59
Change-$0.42 (-8.38%)
Volume$200
Capitalization264.49M
ENTA vs SCPH Comparison Chart in %
Loading...
ENTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SCPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ENTA vs. SCPH commentary
Aug 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ENTA is a Hold and SCPH is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 08, 2025
Stock price -- (ENTA: $6.99 vs. SCPH: $5.01)
Brand notoriety: ENTA and SCPH are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ENTA: 57% vs. SCPH: 110%
Market capitalization -- ENTA: $149.42M vs. SCPH: $264.49M
ENTA [@Biotechnology] is valued at $149.42M. SCPH’s [@Biotechnology] market capitalization is $264.49M. The market cap for tickers in the [@Biotechnology] industry ranges from $199.59B to $0. The average market capitalization across the [@Biotechnology] industry is $2.29B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ENTA’s FA Score shows that 1 FA rating(s) are green whileSCPH’s FA Score has 0 green FA rating(s).

  • ENTA’s FA Score: 1 green, 4 red.
  • SCPH’s FA Score: 0 green, 5 red.
According to our system of comparison, ENTA is a better buy in the long-term than SCPH.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ENTA’s TA Score shows that 4 TA indicator(s) are bullish while SCPH’s TA Score has 4 bullish TA indicator(s).

  • ENTA’s TA Score: 4 bullish, 6 bearish.
  • SCPH’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, SCPH is a better buy in the short-term than ENTA.

Price Growth

ENTA (@Biotechnology) experienced а -7.78% price change this week, while SCPH (@Biotechnology) price change was -1.38% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.18%. For the same industry, the average monthly price growth was +8.39%, and the average quarterly price growth was +12.02%.

Reported Earning Dates

ENTA is expected to report earnings on Aug 11, 2025.

SCPH is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+1.18% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SCPH($264M) has a higher market cap than ENTA($149M). SCPH YTD gains are higher at: 41.525 vs. ENTA (21.565). SCPH (-83.9M) and ENTA (-87.12M) have comparable annual earnings (EBITDA) . ENTA has more cash in the bank: 193M vs. SCPH (57.5M). SCPH has less debt than ENTA: SCPH (52.4M) vs ENTA (58.7M). ENTA has higher revenues than SCPH: ENTA (64.5M) vs SCPH (42M).
ENTASCPHENTA / SCPH
Capitalization149M264M56%
EBITDA-87.12M-83.9M104%
Gain YTD21.56541.52552%
P/E RatioN/AN/A-
Revenue64.5M42M154%
Total Cash193M57.5M336%
Total Debt58.7M52.4M112%
FUNDAMENTALS RATINGS
ENTA vs SCPH: Fundamental Ratings
ENTA
SCPH
OUTLOOK RATING
1..100
6077
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
58
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
4936
P/E GROWTH RATING
1..100
1100
SEASONALITY SCORE
1..100
2850

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SCPH's Valuation (58) in the Pharmaceuticals Major industry is somewhat better than the same rating for ENTA (96) in the Biotechnology industry. This means that SCPH’s stock grew somewhat faster than ENTA’s over the last 12 months.

SCPH's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as ENTA (100) in the Biotechnology industry. This means that SCPH’s stock grew similarly to ENTA’s over the last 12 months.

ENTA's SMR Rating (98) in the Biotechnology industry is in the same range as SCPH (100) in the Pharmaceuticals Major industry. This means that ENTA’s stock grew similarly to SCPH’s over the last 12 months.

SCPH's Price Growth Rating (36) in the Pharmaceuticals Major industry is in the same range as ENTA (49) in the Biotechnology industry. This means that SCPH’s stock grew similarly to ENTA’s over the last 12 months.

ENTA's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for SCPH (100) in the Pharmaceuticals Major industry. This means that ENTA’s stock grew significantly faster than SCPH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ENTASCPH
RSI
ODDS (%)
Bearish Trend 4 days ago
85%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
65%
Bullish Trend 1 day ago
86%
Momentum
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
80%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
83%
Bearish Trend 1 day ago
87%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 11 days ago
71%
Bullish Trend 5 days ago
78%
Declines
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
86%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
69%
Bearish Trend 1 day ago
88%
Aroon
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
ENTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SCPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HSQVY11.380.27
+2.43%
Husqvarna AB
DTNOY13.54N/A
N/A
DNO ASA
VDOMF0.05N/A
N/A
Val D Or Mng Corp.
ELRNF1.85N/A
N/A
Elron Ventures Ltd.
FINMY27.26-1.58
-5.48%
Leonardo S.P.A.

ENTA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ENTA has been loosely correlated with BEAM. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if ENTA jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENTA
1D Price
Change %
ENTA100%
-1.83%
BEAM - ENTA
40%
Loosely correlated
-2.40%
ALEC - ENTA
39%
Loosely correlated
+1.40%
SCPH - ENTA
37%
Loosely correlated
-4.75%
ADCT - ENTA
35%
Loosely correlated
N/A
AURA - ENTA
35%
Loosely correlated
-1.21%
More

SCPH and

Correlation & Price change

A.I.dvisor indicates that over the last year, SCPH has been loosely correlated with AUTL. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if SCPH jumps, then AUTL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SCPH
1D Price
Change %
SCPH100%
-4.75%
AUTL - SCPH
46%
Loosely correlated
+1.73%
AURA - SCPH
43%
Loosely correlated
-1.21%
BEAM - SCPH
42%
Loosely correlated
-2.40%
IPSC - SCPH
42%
Loosely correlated
-2.43%
CRSP - SCPH
41%
Loosely correlated
-0.67%
More